Sareum gets approval for US patent application
7th Jan 2021 12:52
(Sharecast News) - Specialist drug development company Sareum announced on Thursday that the United States Patent and Trademark Office has now formally approved its patent application, number 16/351,620.
Read moreSareum Holdings secures grant for Covid-19 treatment project
3rd Dec 2020 12:19
(Sharecast News) - Specialist drug development company Sareum Holdings announced on Thursday that the grant offer letter from UK Research and Innovation (UKRI) had now been received and approved.
Read moreSareum to get US patent on SDC-1802 programme
8th Oct 2020 15:50
(Sharecast News) - Specialist drug development company Sareum announced on Thursday that the United States Patent and Trademark Office (USPTO) has issued a notice of allowance for a patent on an invention associated with its proprietary 'SDC-1802 TYK2/JAK1 Kinase Inhibitor Programme'.
Read moreSareum Holdings upbeat ahead of cancer research presentation
27th Sep 2019 09:10
(Sharecast News) - Specialist small molecule drug development company Sareum Holdings announced on Friday that it will present new preclinical data from its 'SDC-1802 TYK2/JAK1' inhibitor cancer research programme at the American Association for Cancer Research (AACR) National Cancer Institute (NCI) European Organisation for Research and Treatment of Cancer (EORTC) international conference, in late October in Boston, Massachusetts.
Read moreSareum Holdings expects broadly flat interim losses
27th Aug 2019 08:35
(Sharecast News) - Drug developer Sareum expects interim losses to be broadly flat year-on-year as it continues to focus on the development of multiple treatments for cancer and autoimmune diseases.
Read moreSareum's loss widens as development costs expand
4th Mar 2019 08:26
(Sharecast News) - Sareum Holdings' shares dropped on Monday after the company reported a widened interim loss due to rising costs, though it stated progress had been made with key development programmes.
Read moreSareum flags potentially significant findings for SRA737
28th Feb 2019 14:33
(Sharecast News) - Specialist small molecule drug development company Sareum Holdings announced on Thursday that Sierra Oncology, the licence holder advancing clinical cancer candidate SRA737, had reported that an abstract reporting preclinical data for SRA737 - its Chk1 inhibitor - plus low dose gemcitabine (LDG), in combination with immunotherapy, had been selected for a late-breaking oral presentation at the American Association of Cancer Research annual meeting.
Read moreSareum raises £850,000 to fund cancer inhibitor
26th Oct 2018 08:38
(Sharecast News) - Drug maker Sareum has raised £850,000 to progress the development programme of its cancer inhibitor TYK2/JAK1.
Read moreSareum Holdings selects cancer therapy development candidate
26th Sep 2018 15:20
(Sharecast News) - Drug discovery and development company Sareum Holdings has made the formal selection of a development candidate from its TYK2 inhibitor programme to advance through preclinical development as a potential new targeted therapy for certain cancers, it announced on Wednesday.
Read moreSareum Holdings receives milestone payment
9th Jan 2017 16:39
(ShareCast News) - Sareum Holdings, an AIM listed specialist cancer drug discovery and development company, has announced the attainment of a $2m milestone payment as part of the Chk1 license agreement between its co-investment partner the CRT Pioneer Fund and Sierra Oncology, formerly known as ProN
Read moreSareum reports positive results from TYK2 programme
24th Oct 2016 15:02
(ShareCast News) - Specialist cancer drug discovery and development business Sareum announced a successful conclusion from its feasibility study into the potential for its TYK2 programme lead molecules to treat T-Cell Acute Lymphoblastic Leukaemia (T-ALL) on Monday. The AIM-traded company said the i
Read moreSareum Holdings granted patents in Japan and Singapore
17th Oct 2016 14:16
(ShareCast News) - Specialist cancer drug discovery and development company Sareum announced on Monday that the Japan and Singapore Patent Offices have issued notifications that patents will be granted for inventions associated with its Aurora+FLT3 kinase inhibitor programme. The AIM-traded firm sai
Read moreSareum programme receives patents in Hong Kong and China
3rd Aug 2016 14:56
(ShareCast News) - Specialist cancer drug discovery and development business Sareum announced on Wednesday that the Chinese Patent Office and the Hong Kong Patents Registry have issued notifications that patents will be granted for inventions associated with the company's Aurora+FLT3 Kinase Inhibito
Read moreSareum cancer drug candidate gets MHRA trial approval
5th Apr 2016 12:33
(ShareCast News) - Sareum Holdings was pressing ahead with one of its cancer drug programmes on Tuesday, having received approval from the Medicines and Healthcare products Regulatory Agency (MHRA) for the Clinical Trial Applications submitted for CHK1 inhibitor drug candidate CCT245737. The AIM-tra
Read moreSareum inches closer to drug breakthrough
24th Feb 2016 12:25
(ShareCast News) - Sareum Holdings was still running on the smell of an oily rag in its interim report on Wednesday, but the company was confident it was heading towards a breakthrough in its durgs under development. The AIM-traded cancer drug discovery and development business saw no revenue during
Read more